Somatic mutations of EGFR tyrosine kinase domain are associated with exquisite sensitivity to EGFR-tyrosine kinase inhibitors erlotinib and gefitinib in non-small cell lung cancer (NSCLC) [7-9], but such mutations are rare or absent in CRC [5,10]. This evidence concerns the gene EGFR and colorectal carcinoma.